Arenobufagin

Name: Arenobufagin
Brand: MedChemExpress
SKU: HY-N0876
Rating: 5.0 (4 reviews)

製品番号: HY-N0876 純度: 99.82%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Arenobufagin is a natural bufadienolide that can be extracted from toad venom. Arenobufagin can induce apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Arenobufagin has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells. Arenobufagin can inhibit VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 464-74-4

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 165	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 165	在庫あり	Estimated Time of Arrival: December 31
Solid
1 mg	$60	在庫あり	Estimated Time of Arrival: December 31
5 mg	$150	在庫あり	Estimated Time of Arrival: December 31
10 mg	$240	在庫あり	Estimated Time of Arrival: December 31
50 mg		お問い合わせ
100 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

Other Forms of Arenobufagin:

Arenobufagin (Standard) お問い合わせ

顧客検証

: Arenobufagin purchased from MedChemExpress. Usage Cited in: Molecules. 2017 Sep 11;22(9). pii: E1525. [Abstract]; A549 and NCI-H460 cells are treated with Arenobufagin at the indicated concentrations for 24 h, and protein extracts are subjected to Western blot assay with indicated antibodies;

PI3K アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

Akt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Akt Akt1 Akt2 Akt3

mTOR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

mTOR mTORC1 mTORC2

PARP アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

Caspase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	0.0001 μM Compound: Arenobufagin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30181060]
HepG2	IC₅₀	0.02 μM Compound: Arenobufagin	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 30181060]
HepG2/Adm	IC₅₀	0.056 μM Compound: Arenobufagin	Antiproliferative activity against human HepG2/ADM cells by MTT assay Antiproliferative activity against human HepG2/ADM cells by MTT assay	[PMID: 30181060]
MCF7	IC₅₀	8.88 nM Compound: Arenobufagin	Antiproliferative activity against FAP-alpha deficient human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against FAP-alpha deficient human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 28595013]
MDA-MB-231	IC₅₀	15.67 nM Compound: Arenobufagin	Antiproliferative activity against FAP-alpha deficient human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against FAP-alpha deficient human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 28595013]
MDA-MB-435	IC₅₀	22.45 nM Compound: Arenobufagin	Antiproliferative activity against wild type human MDA-MB-435 cells expressing FAP-alpha incubated for 48 hrs by MTT assay Antiproliferative activity against wild type human MDA-MB-435 cells expressing FAP-alpha incubated for 48 hrs by MTT assay	[PMID: 28595013]

体外実験

Arenobufagin (10 nM-10 μM, 48-72 h) potently inhibits the growth of both HepG2 and HepG2/ADM cells in a dose- and time-dependent manner, with the IC₅₀ of 20.24 and 7.46 nM after 72 h^[1].
Arenobufagin (20-500 nM, 24 h) increases the percentage of apoptotic (annexin positive) cells in HCC cells^[1].
Arenobufagin (20-500 nM, 48 h) induces a specific cleavage of poly (ADP-ribose) polymerase (PARP) and a decrease in pro-caspase-9 and -3^[1].
Arenobufagin (20 nM, 0-24 h) induces autophagic cell death and a significant increase in LC3-II in HepG2/ADM cells^[1].
Arenobufagin (0-500 nM, 0-24 h) inhibits the activation of PI3K/Akt pathways in HCC cells^[1].
Arenobufagin (0-125 nM, 12-48 h) inhibits cell viability in a dose- and time-dependent manner in HUVECs^[2].
Arenobufagin (5-125 nM, 12-48 h) significantly suppresses VEGF-induced HUVECs viability in a dose- and time-dependent manner^[2].
Arenobufagin (0-50 nM, 6 h) inhibits VEGF-induced endothelial cell migration and invasion^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[1]

Cell Line:	Hepatoma carcinoma cells
Concentration:	20, 200, 500 nM
Incubation Time:	24 h
Result:	Depolarized mitochondrial membrane potential dose-dependently.

体内実験

Arenobufagin (3-6 mg/kg, i.p., 28 d) inhibits growth of HepG2/ADM cells xenografts in nude mice^[1].
Arenobufagin (0-10 mg/kg, s.c., 21 d) inhibits VEGF-induced blood vessel formation in C57BL/6J mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice with HepG2/ADM xenografts^[1]
Dosage:	3 and 6 mg/kg
Administration:	Intraperitoneal injection (i.p.), 28 d
Result:	Significantly reduced the tumor volume. Resulted in remarkable decrease in levels of proliferating cell nuclear antigen, PARP, total and phosphorylated mTOR as well as increase of LC3-II. Decreased the degree of phposphorylation of mTOR at Ser²⁴⁴⁸.

分子量

416.51

分子式

C₂₄H₃₂O₆

CAS 番号

464-74-4

Appearance

Solid

Color

White to off-white

SMILES

C[C@]([C@@H](C(C=C1)=COC1=O)CC2)(C3=O)[C@]2([C@@](CC[C@@]4([H])[C@@]5(CC[C@H](O)C4)C)([H])[C@]5([H])[C@@H]3O)O

Structure Classification

Steroids

Initial Source

Animals

toad

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (240.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 10 mg/mL (24.01 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4009 mL	12.0045 mL	24.0090 mL
5 mM	0.4802 mL	2.4009 mL	4.8018 mL
10 mM	0.2401 mL	1.2005 mL	2.4009 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 6.25 mg/mL (15.01 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 6.25 mg/mL (15.01 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 6.25 mg/mL (15.01 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.40 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (2.40 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 1 mg/mL (2.40 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.82%

Select Batch:

データシート (284 KB) SDS (251 KB)

COA (256 KB) HNMR (210 KB) CNMR (171 KB) LCMS (94 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Zhang DM, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 2013 Jun;34(6):1331-42. [Content Brief]

[2]. Li M, et al. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol. 2012 May 1;83(9):1251-60. [Content Brief]

[3]. Cruz Jdos S, et al. Arenobufagin, a compound in toad venom, blocks Na(+)-K+ pump current in cardiac myocytes. Eur J Pharmacol. 1993 Aug 3;239(1-3):223-6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	2.4009 mL	12.0045 mL	24.0090 mL	60.0226 mL
	5 mM	0.4802 mL	2.4009 mL	4.8018 mL	12.0045 mL
	10 mM	0.2401 mL	1.2005 mL	2.4009 mL	6.0023 mL
	15 mM	0.1601 mL	0.8003 mL	1.6006 mL	4.0015 mL
	20 mM	0.1200 mL	0.6002 mL	1.2005 mL	3.0011 mL
DMSO	25 mM	0.0960 mL	0.4802 mL	0.9604 mL	2.4009 mL
	30 mM	0.0800 mL	0.4002 mL	0.8003 mL	2.0008 mL
	40 mM	0.0600 mL	0.3001 mL	0.6002 mL	1.5006 mL
	50 mM	0.0480 mL	0.2401 mL	0.4802 mL	1.2005 mL
	60 mM	0.0400 mL	0.2001 mL	0.4002 mL	1.0004 mL
	80 mM	0.0300 mL	0.1501 mL	0.3001 mL	0.7503 mL
	100 mM	0.0240 mL	0.1200 mL	0.2401 mL	0.6002 mL

Arenobufagin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Arenobufagin464-74-4ApoptosisAutophagyPI3KAktmTORPARPCaspaseAtg8/LC3Phosphoinositide 3-kinasePKBProtein kinase BMammalian target of Rapamycinpoly ADP ribose polymerase Autophagy-related 8;Inhibitorinhibitorinhibit

最近チェックした製品:

製品名

カスタマ需要量 *

お名前 *

タイトル

メールアドレス *

電話番号 *

デパートメント

組纖名 *

市区町村

都道府県

国或いは地域 *

必ず会社名を記載ください。個人への返信は行いません。

備考

製品名

Lot #

お名前 *

メールアドレス *

電話番号 *

部門 *

組纖名 *

国或いは地域 *

備考

Arenobufagin

カスタマーレビュー

Other Forms of Arenobufagin:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

PI3K アイソフォーム固有の製品をすべて表示:

Akt アイソフォーム固有の製品をすべて表示:

mTOR アイソフォーム固有の製品をすべて表示:

PARP アイソフォーム固有の製品をすべて表示:

Caspase アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Arenobufagin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Arenobufagin

カスタマーレビュー

Other Forms of Arenobufagin:

Arenobufagin 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

PI3K アイソフォーム固有の製品をすべて表示:

Akt アイソフォーム固有の製品をすべて表示:

mTOR アイソフォーム固有の製品をすべて表示:

PARP アイソフォーム固有の製品をすべて表示:

Caspase アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Arenobufagin 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Arenobufagin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report